CD30 — Drug Target

All drugs that target CD30 — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

Antibody-drug conjugate (ADC) · Monoclonal antibody-drug conjugate · CD30-targeting antibody-drug conjugate · Antibody-drug conjugate

Marketed (1)

• Brentuximab Vedotin (Bv) · Assistance Publique - Hôpitaux de Paris · Antibody-drug conjugate (ADC) · Oncology
  Brentuximab vedotin is an antibody-drug conjugate that binds to CD30 on tumor cells and delivers a microtubule-disrupting toxin to induce cell death.

Phase 3 pipeline (1)

• Zilovertamab vedotin · Merck Sharp & Dohme LLC · Monoclonal antibody-drug conjugate · Oncology
  Zilovertamab vedotin is a monoclonal antibody-drug conjugate that targets the CD30 antigen.

Phase 2 pipeline (5)

• Consolidation with Brentuximab Vedotin · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · CD30-targeting antibody-drug conjugate · Oncology
  Antibody-drug conjugate targeting CD30
• ABVD and Radiotherapy · Fondazione Italiana Linfomi - ETS · CD30-targeting antibody-drug conjugate · Oncology
  Brentuximab vedotin targets CD30
• Brentuximab Vedotin for Injection · Children's Cancer Group, China · Monoclonal antibody-drug conjugate · Oncology
  Brentuximab vedotin targets CD30, a protein found on the surface of certain cancer cells, and delivers a toxic agent to these cells.
• Antibody-Drug Conjugates · Hellenic Cooperative Oncology Group · Antibody-drug conjugate · Oncology
  Targeting CD30
• Brentuximab Vedotin - induction · The Lymphoma Academic Research Organisation · Monoclonal antibody-drug conjugate · Oncology
  Brentuximab vedotin is a monoclonal antibody-drug conjugate that targets CD30, a protein often found on the surface of Hodgkin lymphoma and anaplastic large cell lymphoma cells.